RankAlpha logo
Back to Rankings

AVBP

ArriVent BioPharmaD
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
The constructive case is that firmonertinib has completed enrollment in the pivotal FURVENT trial with topline data due in mid-2026, ALPACCA has begun dosing in PACC-mutant NSCLC, and the company reported $312.8 million of cash and investments with expected runway into 3Q 2027, limiting near-term financing pressure while multiple oncology shots mature. [#10-K-2026-03-05] [#IR-2026-03-05]
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +20.8.
What can break
FURVENT topline efficacy or safety disappointment would directly impair the core thesis.
Momentum
67
Value
41
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.00 · Bull $42.00 · Bear $19.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-19 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $44.82
Why
Momentum67 · Δ7d +20.8
Value41 · Δ7d -0.0
Sentiment41 · Δ7d +12.8
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
67
26% active weight
Current posture
7d trendFlat
Δ7d
+20.8
Δ21d
-2.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
41
34% active weight
Current posture
7d trendImproving
Δ7d
+12.8
Δ21d
+17.0
Why this grade

Composite grade D. Momentum 66.6 / Value 41.1 / Sentiment 41.1

Fundamentals (TTM)
As of 2026-07-23
Market Cap
$1.47B
Beta
-
Shares Out
46.57M
P/E (TTM) · Derived
-7.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-9.70
Rev YoY
-
EPS YoY
-49.2%
Gross Margin
-
Op Margin
-
Net Debt
-$312.81M
Current Ratio
13.95
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology